To hear about similar clinical trials, please enter your email below
Trial Title:
Clinical-immunological Features of Anti-NMDAR Encephalitis
NCT ID:
NCT05738668
Condition:
Anti NMDA Receptor Encephalitis
Conditions: Official terms:
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Encephalitis
Conditions: Keywords:
Anti NMDA Receptor Encephalitis
antibodies
relapses
outcomes
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
Description of clinical characteristic
Description:
This is a non-interventional study involving clinical data and biological samples (blood,
DNA, CSF). Clinical data are collected for the center and samples are already stored in
biobank repositories and collected as part of "good clinical practice" in the diagnostic
process of patients with suspected autoimmune encephalitis, meaning that the standard
diagnostic and therapeutic approaches will not be altered in the selected study
population. Patients have already gave explicit written consent for biological specimens
sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de
Lyon" (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for
research purposes. Additionally, patients will be informed about the present study.
Arm group label:
Anti-NMDAR encephalitis
Summary:
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess
clinical and immunological prognostic biomarkers
Criteria for eligibility:
Study pop:
Patients with well-characterized anti-NMDAR encephalitis
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patient with neurological disorder
- Patient with NMDAR antibodies in sera or CSF
Exclusion Criteria:
-
- No available clinical data
- Patient without NMDAR antibodies or neurological disorder
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est
Address:
City:
Lyon
Zip:
69677
Country:
France
Start date:
February 1, 2022
Completion date:
February 1, 2025
Lead sponsor:
Agency:
Hospices Civils de Lyon
Agency class:
Other
Source:
Hospices Civils de Lyon
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05738668
